Welcome to our dedicated page for Personalis SEC filings (Ticker: PSNL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Personalis's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Personalis's regulatory disclosures and financial reporting.
Personalis, Inc. reported the results of its 2026 annual meeting of stockholders. Shareholders representing 91,869,300 shares, or 87.76% of the 104,677,900 shares outstanding as of March 17, 2026, were present, establishing a quorum to conduct business.
Two Class I directors, Olivia K. Bloom and Woodrow A. Myers, Jr., M.D., were elected to serve until the 2029 annual meeting, with 75,695,538 and 68,240,509 votes cast in their favor, respectively. Stockholders also ratified BDO USA, P.C. as independent registered public accounting firm for the year ending December 31, 2026, with 91,586,300 votes for. In an advisory vote, stockholders approved the compensation of the company’s named executive officers, with 75,549,455 votes for and relatively few votes against or abstentions.
Personalis, Inc. reported that the Centers for Medicare & Medicaid Services Molecular Diagnostics Program has expanded Medicare coverage for its ultrasensitive NeXT Personal® test. The expansion now includes use of the test for immunotherapy monitoring in patients with late-stage solid tumors.
This change means NeXT Personal can be covered by Medicare when used to track how late-stage solid tumor patients respond to immunotherapy, potentially broadening clinical use within the Medicare population.
Personalis, Inc. ownership disclosure: Deep Track entities and David Kroin report beneficial ownership of 5,760,627 shares of common stock, representing 5.51% of the class. The filing states this position is held with shared voting and shared dispositive power as of May 12, 2026.
The filing identifies Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd. and David Kroin as reporting persons and cites 104,631,832 shares outstanding as of February 20, 2026 for the percent calculation. The filing is a joint Schedule 13G disclosure under applicable ownership rules.
Personalis, Inc. has filed a shelf registration and prospectus to offer and sell up to $150,000,000 of its common stock from time to time under an amended and restated at-the-market sales agreement with Piper Sandler & Co. and BTIG, LLC. Sales may occur on a continuous or delayed basis on the Nasdaq Global Market under the symbol PSNL.
The offering is structured as an at-the-market program and the Sales Agents may sell shares on our behalf for up to the aggregate offering price stated above; the Sales Agents may receive commissions up to 3.00% of gross proceeds.
Personalis, Inc. reported first-quarter 2026 revenue of $15.5 million, down 25% from $20.6 million a year earlier, as pharma testing, enterprise sales, and population sequencing all declined. Enterprise revenue dropped sharply as work with Natera wound down, while VA population sequencing revenue also fell.
Clinical diagnostic revenue rose to $1.4 million from $0.3 million, helped by new Medicare coverage decisions for NeXT Personal Dx in breast cancer and non-small cell lung cancer. Total costs and expenses increased to $47.6 million, leading to a net loss of $30.0 million, compared with a $15.8 million loss a year earlier.
Personalis ended March 31, 2026 with $233.2 million in cash, cash equivalents, and short-term investments and $0.9 million of debt. Operating activities used $22.5 million of cash in the quarter, and the company raised $21.0 million via at-the-market common stock sales.
Personalis, Inc. reported first quarter 2026 revenue of $15.5 million, down from $20.6 million a year earlier as non-core revenue declined while the company shifted focus to its minimal residual disease (MRD) offering. The net loss widened to $30.0 million, compared with $15.8 million in the prior-year quarter, as operating expenses increased.
Clinical test revenue rose to $1.4 million from $0.3 million, with clinical test volume surging 258% year-over-year to 7,815 tests, helped by growth in the NeXT Personal MRD test. Personalis secured Medicare coverage for lung cancer surveillance, adding to existing breast cancer coverage, and ended the quarter with about $233.2 million in cash, cash equivalents and short-term investments.
The company reaffirmed its full-year 2026 outlook, including total revenue of $78.0–$80.0 million, clinical test volume of 43,000–45,000 tests, clinical revenue of $10.0–$11.0 million, gross margin of 15%–20%, a net loss of about $105.0 million, and projected cash usage of about $100.0 million.
PERSONALIS INC filing reports that T. Rowe Price Investment Management, Inc. beneficially owns 4,758,091 shares of Common Stock, representing 4.5% of the class. The filing states all voting and dispositive power is sole rather than shared. The signature is dated 04/08/2026.
Personalis, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 12, 2026. Investors will elect two Class I directors, ratify BDO USA, P.C. as auditor for 2026, and approve on an advisory basis executive pay.
Holders of 104,677,900 common shares as of March 17, 2026 can vote online, by phone, mail, or during the webcast. The board is majority independent, led by an independent chair, and uses three key committees for audit, compensation, and governance oversight. The filing details major stockholders, director experience, and 2025 CEO pay of $3.5 million, including equity and performance-based bonus.
Personalis, Inc. CFO and COO Aaron Tachibana received new equity awards as compensation. He was granted stock options for 206,250 shares of common stock at an exercise price of $6.72 per share, expiring on March 15, 2036. These options vest in 36 equal monthly installments beginning on April 15, 2026.
He also received 34,375 restricted stock units, each representing one share of common stock upon settlement. These RSUs vest in six equal semi-annual installments, with the first tranche vesting on September 15, 2026. Following the RSU grant, he directly holds 198,833 shares of common stock.